Moderna’s $900 Million Cut: Who Shoulders the Risk When the Incentive Shifts?
Starting where most biotech investors instinctively begin, with the question about what the spreadsheet can’t tell you. Moderna’s move to trim $900 million from its 2025 cash-cost guidance isn’t just a CFO flex or a late-night slide for the finance team. It reads like a public map